Download InfoTrac

PrimeZone Media Network, August 4, 2005 pNA
DNAPrint Expands Forensic Service Offerings with Mitochondrial
DNA Testing and Y-Chromosome Testing.
Full Text: COPYRIGHT 2005 News provided by Comtex.
Byline: Staff
SARASOTA, Fla., Aug 4, 2005 (PRIMEZONE via COMTEX) -DNAPrint genomics, Inc. (OTCBB:DNAG) today announced that it has
expanded its DNAWitness(tm) product and service line for the forensic
market with the addition of mitochondrial DNA testing of the maternal line
and Y-chromosome testing for the paternal line. The new services,
DNAWitness-Y and DNAWitness-Mito, became available today.
The DNAWitness(tm) product suite now includes:
DNAWitness 2.5 -- Tests crime scene DNA to assist detectives, forensic
scientists and medical examiners in corroborating eyewitness reports and
confirming suspect identities. DNAWitness 2.5 provides a
BioGeographical Ancestry report that includes a photo database for
reference samples of individuals. Reported ancestral origins are SubSaharan African, Native American, East Asian and Indo-European.
EuroWitness(tm) 1.0 -- Tests crime scene DNA to determine more specific
geographic origins if the test sample ancestry is 50 percent or more IndoEuropean. EuroWitness 1.0 provides a BioGeographical Ancestry report
that includes relative percentages of Northwest European, Southern
European, Middle Eastern or South Asian.
Retinome(tm) -- A predictive test for individual eye color from DNA.
Retinome predicts eye cooler if the sample is 50 percent or greater
European ancestry as to whether eye color is blue, mostly blue, brown or
mostly brown. A representative eye photo database is also provided along
with relevant photo database pictures of the individual references.
STR-Witness(tm) -- A genetic "matching" used as a bar code to track and
report the samples. STR is the same test used for determining an
individual's identity from an available DNA sample. Crime labs run this
test to screen the Federal Bureau of Investigation's Combined DNA Index
System (CODIS) database for possible matches.
DNAWitness-Y -- A new Y-chromosome test that determines the direct
paternal ancestral lineage from the male sex chromosome. DNAWitness-Y
can be used as an identification tool in cases where a mixture of male and
female samples exists.
DNAWitness-Mito -- A new mitochondrial DNA test that examines
ancestral lineages along the maternal line. DNAWitness-Mito can be used
as an identification tool when other DNA testing fails to yield results or the
DNA sample is too deteriorated.
"We are ready to apply our technology anywhere in the world," said
Richard Gabriel, President and Chief Executive Officer of DNAPrint
genomics, Inc. "Our recent acquisition of Trace Genetics expanded our
portfolio of DNA testing services to include mitochondrial for the direct
female line and Y-chromosome for the male-linked genes. These tests
provide detectives a broad array of genetic testing tools to help in
identifying persons of interest from crime scene DNA samples."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomicsbased products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer
genetic tests. The company's first theranostic product (drug/test
combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug
for treatment of anemia in renal dialysis patients (end-stage renal disease).
Currently in pre-clinical development, PT-401 will be targeted to patients
with a genetic profile indicating their propensity to having the best clinical
response. DNAPrint's family of products for the law enforcement forensics
and consumer markets include DNAWitness(tm) RETINOME (tm),
ANCESTRYbyDNA(tm), EURO-DNA(tm).
Forward-Looking Statements
All statements in this press release that are not historical are forwardlooking statements. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of
DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and
patent protection and litigation. DNAPrint genomics, Inc. expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in DNAPrint's expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements are
based.
SOURCE: DNAPrint genomics, Inc.
DNAPrint genomics, Inc.
Richard Gabriel, CEO and President
941 366-3400
-orRon Stabiner
The Wall Street Group, Inc.
212-888-4848
(C) 2005 PRIMEZONE, All rights reserved.
Article A134824993